<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073679</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00014382</org_study_id>
    <secondary_id>150408</secondary_id>
    <nct_id>NCT05073679</nct_id>
  </id_info>
  <brief_title>Oral Naltrexone In Pediatric Eating Disorders</brief_title>
  <acronym>ONPED</acronym>
  <official_title>A Double-Blind Placebo-Controlled Evaluation of Effectiveness of Oral Naltrexone in Management of Adolescent Eating Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rosemary Claire Roden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Miracle Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effectiveness of oral naltrexone tablets in&#xD;
      pediatric and adolescent eating disorders, in particular anorexia nervosa and bulimia&#xD;
      nervosa, as compared to placebo. Study participants will be patients in a partial&#xD;
      hospitalization program or intensive outpatient program for eating disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects participating in this study will receive routine care for eating disorder at a&#xD;
      partial hospitalization (PHP) level of care at MSHMC. In PHP, all patients have weekly&#xD;
      medical screening visits for the duration of their time in care, as well as weekly individual&#xD;
      therapy sessions, individual dietician sessions, and psychiatry appointments. They have&#xD;
      supervised meals and numerous group therapy sessions. Every three weeks, patients in PHP&#xD;
      complete a battery of mood and eating disorder indices including those evaluated in this&#xD;
      study; participants in this study will complete an additional two surveys with this routine&#xD;
      battery. Participants in this study will have no alterations in their routine eating disorder&#xD;
      care outside of study article use and these additional surveys.&#xD;
&#xD;
      Subjects will be enrolled at their first visit for eating disorder programming at child or&#xD;
      adult partial hospitalization (PHP) programming at MSHMC adolescent medicine eating disorders&#xD;
      clinic. Informed consent/assent will be obtained as described above.&#xD;
&#xD;
      The subject will be provided with oral naltrexone or placebo weekly from the MSHMC research&#xD;
      pharmacy. Subjects will be given one weeks' worth of medication at a time. Subjects will be&#xD;
      randomized at enrollment to receive either study drug (naltrexone) or placebo. Participants&#xD;
      or parents of minor participants will be provided study drug or placebo following completion&#xD;
      of urine drug screen and consent/assent. Patients will take the medication daily while they&#xD;
      are in programming; after completion of programming or withdrawal from the study they will no&#xD;
      longer be given study medication. For subjects who are enrolled in child PHP and who eat&#xD;
      meals with parents, the families may choose to administer study drug during meals at&#xD;
      programming. For adult patients enrolled in adult programming, subjects may choose to&#xD;
      self-administer the medication.&#xD;
&#xD;
      On their first contact with PHP, all patients in Child PHP complete various eating disorder&#xD;
      indices as a part of routine care, including the ED-15, EDE-Q, RMCAS, and CDI. This battery&#xD;
      of indices is repeated every 3 weeks while a patient is in programming.&#xD;
&#xD;
      For those who are enrolled in this study, they will complete their routine indices, in&#xD;
      addition they will also complete the BIS/BAS and the ABUSI at enrollment and at weeks 3, 6,&#xD;
      and 9 while in programming. Participants will receive routine eating disorder care while in&#xD;
      PHP.&#xD;
&#xD;
      Patients in Adult PHP typically complete a different inventory every three weeks. If a&#xD;
      patient choses to participate in this study they will be asked to complete the same five&#xD;
      surveys as participants in Child PHP, and they will receive the same amount and type of&#xD;
      compensation.&#xD;
&#xD;
      Six months after enrollment, subjects will be sent copies of ED-15, EDE-Q, RMCAS, CDI,&#xD;
      BIS/BAS, and ABUSI indices either in an in-person medical appointment or via RedCap to&#xD;
      complete. If the patient returns for medical follow-up between 5 and 7 months after&#xD;
      enrollment, their height, weight, and body mass index will also be recorded to determine if&#xD;
      weight restoration was maintained.&#xD;
&#xD;
      At initial contact with the eating disorders clinic, all patients receive an initial battery&#xD;
      of laboratory tests as a part of the standard of care for eating disorder. These tests&#xD;
      include liver function assays and transaminase levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind, placebo controlled randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The Penn State Health IDS pharmacy will purchase Naltrexone 50mg tablets from a pharmaceutical wholesaler. The IDS pharmacy will purchase gelatin capsules and USP grade methylcellulose from a pharmacy supplier to be used for compounding the active and placebo capsules. For the active Naltrexone 50mg capsules, a Naltrexone 50mg tablet will be placed in an empty gelatin capsule with methylcellulose filler. The placebo capsules will be empty gelatin capsules filled with Methylcellulose.&#xD;
Participants will be randomized using redcap at enrollment to either study article or placebo, and neither investigators nor care providers will be aware of which article the participants receive.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ED-15 score</measure>
    <time_frame>Time Frame: Measured at the following timepoints: enrollment</time_frame>
    <description>ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED-15 score</measure>
    <time_frame>Time Frame: Measured at the following timepoints: one week</time_frame>
    <description>ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED-15 score</measure>
    <time_frame>Time Frame: Measured at the following timepoints: three week</time_frame>
    <description>ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED-15 score</measure>
    <time_frame>Time Frame: Measured at the following timepoints: six weeks</time_frame>
    <description>ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED-15 score</measure>
    <time_frame>Time Frame: Measured at the following timepoints: nine weeks (last week of treatment)</time_frame>
    <description>ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED-15 score</measure>
    <time_frame>Time Frame: Measured at the following timepoints: 6 months after enrollment</time_frame>
    <description>ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire score (EDE-Q)</measure>
    <time_frame>Measured at the following timepoints: enrollment</time_frame>
    <description>EDE-Q is an evidence-based metric of eating disorder severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire score (EDE-Q)</measure>
    <time_frame>Measured at the following timepoints: one week</time_frame>
    <description>EDE-Q is an evidence-based metric of eating disorder severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire score (EDE-Q)</measure>
    <time_frame>Measured at the following timepoints: three weeks</time_frame>
    <description>EDE-Q is an evidence-based metric of eating disorder severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire score (EDE-Q)</measure>
    <time_frame>Measured at the following timepoints: six weeks</time_frame>
    <description>EDE-Q is an evidence-based metric of eating disorder severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire score (EDE-Q)</measure>
    <time_frame>Measured at the following timepoints: nine weeks (last week of treatment)</time_frame>
    <description>EDE-Q is an evidence-based metric of eating disorder severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Disorder Examination Questionnaire score (EDE-Q)</measure>
    <time_frame>Measured at the following timepoints: 6 months after enrollment</time_frame>
    <description>EDE-Q is an evidence-based metric of eating disorder severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory score</measure>
    <time_frame>Measured at the following timepoints: enrollment</time_frame>
    <description>Evidence-based metric of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory score</measure>
    <time_frame>Measured at the following timepoints: one week</time_frame>
    <description>Evidence-based metric of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory score</measure>
    <time_frame>Measured at the following timepoints: three weeks</time_frame>
    <description>Evidence-based metric of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory score</measure>
    <time_frame>Measured at the following timepoints: six weeks</time_frame>
    <description>Evidence-based metric of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory score</measure>
    <time_frame>Measured at the following timepoints: nine weeks (last week of treatment)</time_frame>
    <description>Evidence-based metric of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Inventory score</measure>
    <time_frame>Measured at the following timepoints: 6 months after enrollment</time_frame>
    <description>Evidence-based metric of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Children's Manifest Anxiety Scale</measure>
    <time_frame>Measured at the following timepoints: enrollment</time_frame>
    <description>evidence-based metric of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Children's Manifest Anxiety Scale</measure>
    <time_frame>Measured at the following timepoints: one week</time_frame>
    <description>evidence-based metric of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Children's Manifest Anxiety Scale</measure>
    <time_frame>Measured at the following timepoints: three weeks</time_frame>
    <description>evidence-based metric of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Children's Manifest Anxiety Scale</measure>
    <time_frame>Measured at the following timepoints: six weeks</time_frame>
    <description>evidence-based metric of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Children's Manifest Anxiety Scale</measure>
    <time_frame>Measured at the following timepoints: nine weeks (last week of treatment)</time_frame>
    <description>evidence-based metric of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Children's Manifest Anxiety Scale</measure>
    <time_frame>Measured at the following timepoints: 6 months after enrollment</time_frame>
    <description>evidence-based metric of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexian Brothers Urge to Self-Injure Scale (ABUSI)</measure>
    <time_frame>Measured at the following timepoints: enrollment</time_frame>
    <description>evidence-based metric of urge to self-harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexian Brothers Urge to Self-Injure Scale (ABUSI)</measure>
    <time_frame>Measured at the following timepoints: one week</time_frame>
    <description>evidence-based metric of urge to self-harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexian Brothers Urge to Self-Injure Scale (ABUSI)</measure>
    <time_frame>Measured at the following timepoints: three weeks</time_frame>
    <description>evidence-based metric of urge to self-harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexian Brothers Urge to Self-Injure Scale (ABUSI)</measure>
    <time_frame>Measured at the following timepoints: six weeks</time_frame>
    <description>evidence-based metric of urge to self-harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexian Brothers Urge to Self-Injure Scale (ABUSI)</measure>
    <time_frame>Measured at the following timepoints: nine weeks (last week of treatment)</time_frame>
    <description>evidence-based metric of urge to self-harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alexian Brothers Urge to Self-Injure Scale (ABUSI)</measure>
    <time_frame>Measured at the following timepoints: 6 months after enrollment</time_frame>
    <description>evidence-based metric of urge to self-harm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)</measure>
    <time_frame>Measured at the following timepoints: enrollment</time_frame>
    <description>Evidence-based metric of impulsivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)</measure>
    <time_frame>Measured at the following timepoints: one week</time_frame>
    <description>Evidence-based metric of impulsivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)</measure>
    <time_frame>Measured at the following timepoints: three weeks</time_frame>
    <description>Evidence-based metric of impulsivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)</measure>
    <time_frame>Measured at the following timepoints: six weeks</time_frame>
    <description>Evidence-based metric of impulsivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)</measure>
    <time_frame>Measured at the following timepoints: nine weeks (last week of treatment)</time_frame>
    <description>Evidence-based metric of impulsivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)</measure>
    <time_frame>Measured at the following timepoints: 6 months after enrollment</time_frame>
    <description>Evidence-based metric of impulsivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of weight restoration</measure>
    <time_frame>Will evaluate total rate of weight restoration via chart review at the end of the study</time_frame>
    <description>For participants who need to restore weight, will evaluate the rate of weight gain in care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of weight restoration</measure>
    <time_frame>Will evaluate total rate of weight restoration via chart review 6 months after enrollment</time_frame>
    <description>For participants who need to restore weight, will evaluate the rate of weight gain in care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need For Higher Level of Care</measure>
    <time_frame>Will evaluate total rate of weight restoration via chart review at the end of the study</time_frame>
    <description>Need to leave the current level of care (where the study is being conducted) to go to a residential, inpatient, or hospital facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need For Higher Level of Care</measure>
    <time_frame>Will evaluate total rate of weight restoration via chart review 6 months after enrollment</time_frame>
    <description>Need to leave the current level of care (where the study is being conducted) to go to a residential, inpatient, or hospital facility</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>enrollment for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 1 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 2 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 3 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 4 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 5 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 6 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 7 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 8 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>week 9 for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>6 months after enrollment for patients age 17 or older</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>enrollment for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 1 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 2 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 3 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 4 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 5 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 6 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 7 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 8 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>week 9 for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Ask Suicide Screening Questions (ASQ)</measure>
    <time_frame>6 months after enrollment for patients age 16 or younger</time_frame>
    <description>Evidence-based metric evaluating for presence of suicidal ideation and severity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anorexia Nervosa/Bulimia</condition>
  <condition>Anorexia in Adolescence</condition>
  <condition>Anorexia Nervosa, Atypical</condition>
  <condition>Anorexia Nervosa, Binge Eating/Purging Type</condition>
  <condition>Purging (Eating Disorders)</condition>
  <condition>Impulsive Behavior</condition>
  <condition>Eating Disorders</condition>
  <condition>Bulimia Nervosa</condition>
  <condition>Eating Disorders in Adolescence</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral naltrexone, to start as 25mg for three days then 50mg a day thereafter for up to nine weeks or completion of higher level of care, whichever haver happens first. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for nine weeks or until completion of higher level of care, whichever happens first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Hydrochloride</intervention_name>
    <description>25mg x 3 days then 50mg a day thereafter</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Methylcellulose and gelatin capsule only</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 13-18 (inclusive)&#xD;
&#xD;
          -  Any sex&#xD;
&#xD;
          -  Diagnoses of anorexia nervosa binge-purge subtype, bulimia nervosa, purging disorder,&#xD;
             or atypical anorexia nervosa with bingeing or purging behaviors according to the&#xD;
             Diagnostic and Statistical Manual version 5 diagnostic criteria&#xD;
&#xD;
          -  Electing to participate in child or adult partial hospitalization program for eating&#xD;
             disorder treatment at MSHMC&#xD;
&#xD;
        The diagnostic criteria for anorexia nervosa, binge-purge subtype, are:&#xD;
&#xD;
        A. Restriction of energy intake relative to requirements, leading to a significantly low&#xD;
        body weight in the context of age, sex, developmental trajectory, and physical health.&#xD;
        Significantly low weight is defined as a weight that is less than minimally normal or, for&#xD;
        children and adolescents, less than minimally expected.&#xD;
&#xD;
        B. Intense fear of gaining weight or of becoming fat, or persistent behavior that&#xD;
        interferes with weight gain, even though at a significantly low weight.&#xD;
&#xD;
        C. Disturbance in the way in which one's body weight or shape is experienced, undue&#xD;
        influence of body weight or shape on self-evaluation, or persistent lack of recognition of&#xD;
        the seriousness of the current low body weight D. During the last three months the&#xD;
        individual has engaged in recurrent episodes of binge eating or purging behaviour (i.e.&#xD;
        self-induced vomiting, or the misuse of laxatives, diuretics, or enemas).19 E. A diagnosis&#xD;
        of atypical anorexia nervosa can be made when the body weight is normal or high If these&#xD;
        patients engage in bingeing or purging behaviors as defined in anorexia nervosa,&#xD;
        binge-purge subtype, they are eligible for inclusion in this study&#xD;
&#xD;
        The diagnostic criteria for bulimia nervosa are:&#xD;
&#xD;
        A. Recurrent episodes of binge eating. An episode of binge eating is characterized by&#xD;
&#xD;
        B. both:&#xD;
&#xD;
        i. Eating in a discrete period of time (e.g. within any 2 hour period), an amount of food&#xD;
        that is definitely larger than what most individuals would eat in a similar period of time&#xD;
        under similar circumstances; ii. A sense of lack of control over eating during the episodes&#xD;
        (e.g. a feeling that one cannot stop eating or control what or how much one is eating.&#xD;
&#xD;
        C. Recurrent inappropriate compensatory behaviors to prevent weight gain, such as&#xD;
        self-induced vomiting; misuse of laxatives, diuretics, or other medications; fasting; or&#xD;
        excessive exercise.&#xD;
&#xD;
        D. The binge eating and inappropriate compensatory behaviors both occur, on average, at&#xD;
        least once a week for 3 months.&#xD;
&#xD;
        E. Self-evaluation is unduly influenced by body shape and weight. F. The disturbance does&#xD;
        not occur exclusively during episodes of anorexia nervosa.&#xD;
&#xD;
        â€¢ The diagnostic criteria for purging disorder are: recurrent purging behavior to influence&#xD;
        weight or shape (e.g. self-induced vomiting; misuse of laxatives, diuretics, or other&#xD;
        medications) in the absence of binge eating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of intellectual disability&#xD;
&#xD;
          -  History of gender dysphoria&#xD;
&#xD;
          -  History of known genetic or neurologic disease&#xD;
&#xD;
          -  Need for treatment with opioid painkillers&#xD;
&#xD;
          -  Weight &lt;25kg&#xD;
&#xD;
          -  Inability to swallow pills&#xD;
&#xD;
          -  Lack of proficiency in written or spoken English&#xD;
&#xD;
          -  Urine drug screen positive for opioids at enrollment&#xD;
&#xD;
          -  Positive serum pregnancy test at enrollment&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Elevation of three times the upper limit of normal for age in either alanine&#xD;
             aminotransferase (ALT) or asparagine aminotransferase (AST).High risk of suicide at&#xD;
             enrollment on Columbia Suicide Severity Rating Scale (C-SSRS, for participants age 18)&#xD;
             or Ask Suicide Screening Questions (ASQ, participants age 13 to 17)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosemary C Roden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PennState Health Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosemary C Roden, MD</last_name>
    <phone>717-531-7235</phone>
    <email>rroden@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marley Billman, BS</last_name>
    <phone>7175311383</phone>
    <email>mbillman@pennstatehealth.psu.edu</email>
  </overall_contact_backup>
  <link>
    <url>https://journals.sagepub.com/doi/full/10.1177/0734282915580763</url>
    <description>RMCAS</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/232481813_Behavioral_Inhibition_Behavioral_Activation_and_Affective_Responses_to_Impending_Reward_and_Punishment_The_BISBAS_Scales</url>
    <description>BIS/BAS</description>
  </link>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf</url>
    <description>Oral naltrexone package insert</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/258253416_Feeding_and_Eating_Disorders_in_DSM-5</url>
    <description>DSM-5 Chapter on Feeding and Eating Disorders</description>
  </link>
  <reference>
    <citation>Tatham M, Turner H, Mountford VA, Tritt A, Dyas R, Waller G. Development, psychometric properties and preliminary clinical validation of a brief, session-by-session measure of eating disorder cognitions and behaviors: The ED-15. Int J Eat Disord. 2015 Nov;48(7):1005-15. doi: 10.1002/eat.22430. Epub 2015 May 26.</citation>
    <PMID>26011054</PMID>
  </reference>
  <reference>
    <citation>Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994 Dec;16(4):363-70.</citation>
    <PMID>7866415</PMID>
  </reference>
  <reference>
    <citation>Smucker MR, Craighead WE, Craighead LW, Green BJ. Normative and reliability data for the Children's Depression Inventory. J Abnorm Child Psychol. 1986 Mar;14(1):25-39.</citation>
    <PMID>3950219</PMID>
  </reference>
  <reference>
    <citation>Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.</citation>
    <PMID>22193671</PMID>
  </reference>
  <reference>
    <citation>Horowitz LM, Bridge JA, Teach SJ, Ballard E, Klima J, Rosenstein DL, Wharff EA, Ginnis K, Cannon E, Joshi P, Pao M. Ask Suicide-Screening Questions (ASQ): a brief instrument for the pediatric emergency department. Arch Pediatr Adolesc Med. 2012 Dec;166(12):1170-6. doi: 10.1001/archpediatrics.2012.1276.</citation>
    <PMID>23027429</PMID>
  </reference>
  <reference>
    <citation>Campbell K, Peebles R. Eating disorders in children and adolescents: state of the art review. Pediatrics. 2014 Sep;134(3):582-92. doi: 10.1542/peds.2014-0194. Review.</citation>
    <PMID>25157017</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Rosemary Claire Roden</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
    <mesh_term>Impulsive Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

